Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 8/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25413286 | 0.94 | NOS2 (0.46) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL26313835 | 0.87 | NOS2 (0.47) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL30597321 | 0.82 | NOS2 (0.44) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL26317567 | 0.82 | NOS2 (0.44) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL26313833 | 0.82 | NOS2 (0.43) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL30597301 | 0.82 | NOS2 (0.43) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL26317956 | 0.77 | AAK1 (0.39) | AAK1CCR2 | |
| SCHEMBL25412228 | 0.76 | NOS2 (0.55) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL6488980 | 0.72 | NOS2 (0.65) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL25412029 | 0.72 | NOS2 (0.49) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | NOS1, NOS3, NOS2 | NOS2 3/4885CYP2D6 360/4885SLC6A2 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.